Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Newish Technology (beijing) Co., Ltd.

Newish Technology Co., Ltd.

Jianhe Chen

Jing Su

Petrus Johannes Louis Spee

Henrik Oestergaard

Laust Bruun Johnsen

Prafull S Gandhi

Rong Zhou

Karina Thorn

Per J Greisen

Mikkel Nors Harndahl

Jinchao Zhang

Bjarne Gram Hansen

Haisun Zhu

Morten Groenbech Rasch

Jiujiu Yu

Zhiru Yang

Jing Wang

Jing Li

Jesper F Lau

Patrick William Garibay

Janos Tibor Kodra

Henning Thoegersen

Birgit Wieczorek

Lars Linderoth

Anders Svensson

Soren Berg Padkjaer

Helle Demuth

Qin Han

Leif Noerskov-Lauritsen

Peter Thygesen

Henning THØGERSEN

Søren Berg Padkjær

Christine Brunn Schioedt

Kanghua Li

Hongling Li

Chunhua Zhao

Salka Elboel Rasmussen

Eva Johansson

Salka Elbøl Rasmussen

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

Procoagulant antibodies

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.

EGF(A) analogues with fatty acid substituents

Provided are a sub-totipotent stem cell product and epigenetic modification label thereof, a method for inducing the generation of the sub-totipotent stem cell product and identification for the epigenetic modification label of the differentiation potential of stem cells. Also provided is a use of histone modification states of sub-totipotent genes and/or differentiation related genes to predict the epigenetic modification label of the differentiation potentials of stem cells.

Sub-totipotent stem cell product and apparent hereditary modifying label thereof

The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.

Humanized anti-human NKG2A monoclonal antibody

The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.

Stable growth hormone compounds resistant to proteolytic degradation

Growing community of inventors

Beijing, China

Jianhe Chen